VIDEO: CLEAR Outcomes trial shows statin-intolerant patients benefit from bempedoic acid

The late-breaking CLEAR Outcomes trial presented at the 2023 American College of Cardiology (ACC) meeting found bempedoic acid can be used in statin-intolerant patients to reduce low-density lipoprotein (LDL) cholesterol levels. This large study also found a low incidence of muscle-related adverse events, which is a common complaint among statin-intolerant patients.[1]

Steven Nissen, MD, chief academic officer of Cleveland Clinic's Heart, Vascular and Thoracic Institute, spoke to Cardiovascular Business about the trial's results and what they could mean for patient care going forward.